Assenagon Asset Management S.A. Sells 61,087 Shares of DaVita Inc. (NYSE:DVA)

Assenagon Asset Management S.A. lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 81.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,530 shares of the company’s stock after selling 61,087 shares during the quarter. Assenagon Asset Management S.A.’s holdings in DaVita were worth $2,070,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Copia Wealth Management bought a new position in shares of DaVita in the 4th quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita in the 4th quarter worth approximately $41,000. Coppell Advisory Solutions LLC boosted its stake in DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Canada Post Corp Registered Pension Plan bought a new position in DaVita in the 4th quarter valued at approximately $55,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of research analyst reports. Truist Financial lowered their price objective on shares of DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a research report on Monday, May 19th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Stock Performance

DVA opened at $137.83 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The company has a market cap of $10.41 billion, a P/E ratio of 12.83, a price-to-earnings-growth ratio of 1.07 and a beta of 1.11. The firm’s 50-day moving average price is $141.25 and its 200-day moving average price is $150.78.

DaVita (NYSE:DVA) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter last year, the company posted $2.26 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.